Durect Corporation is a specialty pharmaceutical company focused on the development of pharmaceutical products based on its drug delivery technology platforms. The Company�s product pipeline, as of December 31, 2012, consisted of eight investigational drug candidates in clinical development, with one program the subject of a New Drug Application (NDA) with the United States Food and Drug Administration (FDA), with one program in Phase III with an NDA in preparation, two programs in Phase II and three programs in Phase I. The Company�s products candidates include Remoxy, POSIDUR, ELADUR, TRANSDUR-Sufentanil, Relday, ORADUR-based opioid, ORADUR-ADHD, Relday and other products. The Company's developments are focused on the application of its drug delivery technologies to potential products in a variety of chronic and episodic disease areas, including pain, central nervous system (CNS) disorders, cardiovascular disease and other chronic diseases.